Table 4.

Prognostic factors influencing on remission rates, relapse-free survival and overall survival

				Relapse-free survival		Overall survival
Variable	Category	CR rate (%)
			p	Median months (95% C.I.)	p	Median months (95% C.I.)
Age	≤20	100	0.17	12.2 (0.0–29.6)	0.87	16.7 (3.3–30.1)	0.46
	>20	82.1		11.5 (7.3–15.7)		16.0 (11.2–20.8)
Sex	male	83.3	0.68	8.3 (2.1–14.5)	0.05	13.1 (8.7–17.5)	0.04
	female	91.3		43.7 (0.0–87.7)		52.2 (12.9–91.5)
WBC (×109/L)	<30	91.2	0.23	12.9 (5.4–20.4)	0.71	19.6 (10.6–28.6)	0.30
	≥30	78.9		11.5 (7.5–15.5)		14.4 (11.4–17.4)
LDH (U/L)	<1,000	89.7	0.42	12.9	0.27	19.6 (15.9–23.3)	0.09
	≥1,000	80.0		10.0 (2.6–17.4)		12.8 (8.0–17.6)
Hepatomegaly	absent	84.0	0.69	13.0 (5.6–20.4)	0.41	19.6 (12.0–27.2)	0.45
	present	88.9		10.0 (0.8–19.2)		14.4 (12.0–16.8)
Splenomegaly	absent	82.1	0.43	10.2 (3.2–17.2)	0.70	16.0 (10.8–21.2)	0.61
	present	91.7		12.2 (4.3–20.1)		15.2 (9.7–20.7)
Lymphadenopathy	absent	89.2	0.39	11.5 (7.2–15.8)	0.79	16.0 (8.4–23.6)	0.70
	present	80.0		12.8		16.7 (6.5–26.9)
Mediastinal mass	absent	87.2	1.00	12.9 (8.3–17.5)	0.03	17.1 (11.7–22.5)	0.21
	present	83.3		2.6 (1.3–3.9)		5.9 (0.0–19.6)
Infection at presentation	absent	90.5	0.14	10.0 (5.3–14.7)	0.26	16.0 (12.5–19.5)	0.97
	present	72.7		15.3		17.1 (3.1–31.1)
Ph/bcr-abl	absent	83.8	1.00	15.3 (0.0–32.5)	0.09	17.3 (11.0–23.6)	0.16
	present	88.9		3.7 (0.6–6.8)		10.8 (5.5–16.1)
FAB subtype	L1	91.7	0.15	12.9 (8.8–17.0)	0.71	17.3 (14.0–20.6)	0.27
	L2	71.4		8.3 (0.0–17.6)		11.0 (7.1–14.9)
Immunophenotype	B-cell precursor	91.7	0.13	11.5 (4.2–18.8)	0.13	16.0 (10.1–21.9)	0.09
	T-cell	75.0		10.0 (0.0–26.7)		15.2 (0.0–31.3)
No. of induction to CR	one			12.9 (0.0–36.1)	0.003	19.6 (0.0–44.1)	0.01
	two			3.4 (1.4–5.4)		10.8 (0.0–21.7)

CR, complete remission